This week the FDA will vote on flibanserin, the much-talked-about drug for women with the condition called hypoactive sexual desire disorder or — because everything in sexual health needs an acronym like ED or PE — HSDD.
On the eve of the FDA vote, CBS last week ran still another story about flibanserin. This drug has received so much news coverage, you’d think it cures cancer.
And CBS did little more than promote the hype even more, saying FDA approval “could translate into a $2 billion market in this country alone” and then failing to challenge the disease-mongering estimate of “10 percent to 30 percent of women” with this condition. It all just goes along with the drug company’s efforts to build a demand before the drug is even approved. Read more »
*This blog post was originally published at Gary Schwitzer's HealthNewsReview Blog*
[On April 8th] at the University of California at Los Angeles, a rally [was] planned to raise awareness about the value of responsible animal research and to denounce acts of terrorism toward animal researchers and their families. The highlight of the “Pro-Test” rally [was] the presentation to legislators and the media a petition with nearly 12,000 signatures of scientists who support the use of animals in research.
The rally and the petition drive [was] a joint effort of Americans for Medical Progress, Pro-Test for Science, and Speaking of Research.
I stand together with my colleagues who conduct animal research in honor of their application of knowledge to advance biology and relieve human suffering, all while a growing movement of animal rights activists up the ante from protests to attacks on researchers, destruction of homes by arson, and even the vandalism of graves of researchers’ loved ones. Read more »
*This blog post was originally published at Terra Sigillata*